肌少症对肺癌预后价值的系统评价与荟萃分析
该系统评价与荟萃分析纳入13项队列研究共1810例肺癌患者,评估肌少症的预后价值。结果显示非小细胞肺癌和小细胞肺癌中肌少症患病率分别为43%和52%,肌少症与更短的总生存期显著相关(HR 2.23,95%CI 1.68-2.94),但在非小细胞肺癌中与无病生存期无关。
要点
- 肺癌患者肌少症患病率高,非小细胞肺癌43%、小细胞肺癌52%。
- 肌少症是肺癌总生存期缩短的重要预测因素(HR 2.23)。
- 肌少症对非小细胞肺癌各期总生存期均有独立预测价值。
核心结论
- 肌少症在肺癌患者中高度流行(约每两人中有一人),并且是小细胞肺癌及不同分期非小细胞肺癌总生存期受损的重要预测因素。
研究设计与样本
- 系统评价与荟萃分析,检索Ovid MEDLINE、Embase和Cochrane Central Register of Controlled Trials至2018年7月23日,纳入回顾性或前瞻性队列研究,共13项研究、1810例参与者。
主要发现
- 非小细胞肺癌患者肌少症合并患病率为43%,小细胞肺癌为52%。
- 肌少症与肺癌患者更短的总生存期相关(HR 2.23;95% CI 1.68-2.94)。
- 该关联见于非小细胞肺癌(HR 2.57;95% CI 1.79-3.68)和小细胞肺癌(HR 1.59;95% CI 1.17-2.14)。
- 肌少症是I-II期非小细胞肺癌(HR 3.23;95% CI 1.68-6.23)和III-IV期非小细胞肺癌(HR 2.19;95% CI 1.14-4.24)总生存期缩短的独立预测因素。
- 肌少症不是非小细胞肺癌患者无病生存期的独立预测因素(HR 1.28;95% CI 0.44-3.69)。
临床怎么用
- 在肺癌患者中应关注肌少症的评估,因其与总生存期缩短相关,尤其对非小细胞肺癌各期和小细胞肺癌患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence regarding the association between sarcopenia (skeletal muscle depletion) and outcomes in patients with lung cancer varies across studies. We aimed to systematically review the prognostic value of sarcopenia in lung cancer. METHODS: We searched Ovid MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials through July 23, 2018 to identify retrospective or prospective cohort studies. We applied the Quality in Prognostic Studies instrument to assess the risk of bias in individual studies. We examined the heterogeneity and publication bias and performed subgroup analyses and sensitivity analyses. RESULTS: We included 13 studies (1,810 participants). The pooled prevalence of sarcopenia was 43% in patients with non-small cell lung cancer (NSCLC) and 52% in patients with small cell lung cancer (SCLC). Sarcopenia was associated with a shorter overall survival (OS) in patients with lung cancer (hazard ratio [HR], 2.23; 95% CI, 1.68-2.94). This association existed for both NSCLC (HR, 2.57; 95% CI, 1.79-3.68) and SCLC (HR, 1.59; 95% CI, 1.17-2.14). Sarcopenia was an independent predictor of shorter OS in both stage I-II NSCLC (HR, 3.23; 95% CI, 1.68-6.23) and stage III-IV NSCLC (HR, 2.19; 95% CI, 1.14-4.24). However, sarcopenia was not an independent predictor of disease-free survival in patients with NSCLC (HR, 1.28; 95% CI, 0.44-3.69). CONCLUSIONS: Sarcopenia is highly prevalent in patients with lung cancer (approximately one in two) and an important predictor of impaired OS in patients with SCLC or with different stages of NSCLC.
引用
- Yang M, Shen Y, Tan L, et al. Prognostic Value of Sarcopenia in Lung Cancer: A Systematic Review and Meta-analysis. Chest. 2019. PMID: 31128115. doi:10.1016/j.chest.2019.04.115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。